The Parkinson's-Reversing Breakthrough

Treatment for Parkinson Disease

Get Instant Access

1. Factor SA. Dopamine Agonists. Med Clin North Am 1999; 83:415-443.

2. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002; 287:1653-1661.

3. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54:93-101.

4. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 2006; 21:343-353.

5. Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 2001; 18:389-396.

6. Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin Neu-ropharmacol 2001; 24:247-253.

7. Pierantozzi M, Palmieri MG, Mazzone P, et al. Deep brain stimulation of both subthala-mic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study. Clin Neu-rophysiol 2002; 113:108-113.

8. Koller W, Stacy M. Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology 2004; 62(6 suppl 4):S22-S26.

9. Manson AJ, Hanagasi H, Turner K, et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001; 124(Pt 2):331-340.

10. Lewitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004; 62(6 suppl 4):S8-S11.

11. Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 2004; 62(6 suppl 4):S32-S36.

12. Poewe W, Wenning GK. Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord 2000; 15:789-794.

13. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58:1385-1392.

14. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001; 22:93-94.

15. Pahwa R, Lyons KE. Solving the puzzle of Parkinson's therapy. Practical Neurology 2002; Feb:17-18, 22-24.

16. Goetz CG, Tanner CM, Glantz RH, Klawans HL. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 1985; 35:749-751.

17. Physician's Desk Reference. 60th ed. Montvale, NJ: Thomson PDR, 2006.

18. Factor SA, Weiner WJ. Viewpoint: Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993; 8:257-262.

19. Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease. Cochrane Database Syst Rev 2000; (2):CD000236.

20. Ramaker C, van Hilten JJ. Bromocriptine versus levodopa in early Parkinson's disease. Cochrane Database Syst Rev 2000; (3):CD002258.

21. van Hilten JJ, Ramaker C, Van de Beek WJ, Finken MJ. Bromocriptine for levodopa-induced motor complications in Parkinson's disease. Cochrane Database Syst Rev 2000; (2):CD001203.

22. Guttman M, International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997; 49:1060-1065.

23. Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology 1985; 35:296-299.

24. Bonuccelli U, Colzi A, Del Dotto P. Pergolide in the treatment of patients with early and advanced Parkinson's disease. Clin Neuropharmacol 2002; 25:1-10.

25. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995; 45(suppl):S13-S21.

26. Olanow CW, Fahn S, Muenter M, et al. A Multicenter double-blind placebo controlled trial of pergolide as adjunct to Sinemet in the treatment of Parkinson's disease. Mov Disord 1994; 9:40-47.

27. Tintner R, Manian P, Gauthier P, Jankovic J. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol 2005; 62:1290-1295.

28. Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005; 80:1016-1020.

29. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18; 338-347.

30. Lieberman AN, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a randomized, placebo-controlled, parallel group study. Neurology 1997; 49:162-168.

31. Parkinson Study Group. Pramipexole vs. levodopa as and initial treatment for Parkinson disease. JAMA 2000; 284:1931-1938.

32. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61:1044-1053.

33. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999; 66:436-441.

34. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel; motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52:1908-1910.

35. Stacy M. Sleep disorders in Parkinson's disease: Epidemiology and management. Drugs Aging 2002; 19:733-739.

36. Rissling I, Geller F, Bandmann O, et al. Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks". Mov Disord 2004; 19:1279-1284.

37. Samanta JES, Stacy M. Pathologic Gambling in Parkinson's disease. Mov Disord 1998; 15(suppl 3):111.

38. Gschwandtner U, Astar J, Renard S, Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001; 24:170-172.

39. Dodd ML, Kloss KJ, Bower KH, et al. Pathological gambling caused by drugs used to treat Parkinson's disease. Arch Neurol 2005; 62:1-5.

40. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998; 51:1057-1061.

41. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997; 49:393-399.

42. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342:1484-1491.

43. Lang AE, Rascol O, Brooks DJ, et al. The development of dyskinesias in Parkinson's disease patients receiving ropinirole and given supplemental l-dopa. Neurology 2002; 58(suppl 3):A82.

44. Pahwa R, Factor SA, Elmer LW. Ropinirole 24-hour prolonged release reduces awake time spent "off " in patients with Parkinson's disease not optimally controlled with L-dopa. Neurology 2006; 66(suppl 2):A292-A293.

45. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergo-line taken once daily in Parkinson's disease. Neurology 1996; 46:1062-1065.

46. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist caber-goline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004; 18:733-746.

47. Clarke CE, Deane KD. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2001; (1):CD001519.

48. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005; 353:1976-1977.

49. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005; 65(suppl 1):S3-S5.

50. Pfeiffer RF. A promising new technology for Parkinson's disease. Neurology 2005; 65(suppl 1):S6-S10.

51. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch. Neurol. 2003; 60:1721-1728.

52. Watts RL, Wendt RL, Nausieda P. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early stage, idiopathic Parkinson's disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial. Mov Disord 2004; 10(suppl 9):S258.

53. LeWitt P, Nausieda P, Chang F-L, et al. Rotigotine transdermal system in a multicenter trial of patients with advanced-stage Parkinson's disease as adjunctive therapy to lev-odopa. Neurology 2006; 66(suppl 2):A184-A185.

54. Simon N, Micallef J, Reynier JC, et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmaco-kinetic/pharmacodynamic, randomized, double-blind study. Mov Disord 2005; 20(7):803-809.

55. Castro-Caldas A, Delwaide P, Jost W, et al. The Parkinson-Control study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/d) with bromocriptine (25mg/d) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21:500-509.

56. Hanna PA, Ratkos L, Ondo WG, et al. A comparison of the therapeutic efficacy of pergolide and pramipexole in Parkinson's disease. J Neural Transm 2001; 108:63-70.

57. Hauser R, Reider C, Stacy M, et al. Acute vs. gradual pramipexole to ropinirole switch. Mov Disord 1998; 15(suppl):133.

58. Olanow CW, Koller WC. An algorithm for the management of Parkinson's disease. Neurology 1998; 50(suppl):S10-S14.

59. Poewe W. Should treatment of Parkinson's disease be started with a dopamine agonist? Neurology 1998; 51(suppl):S21-S24.

Was this article helpful?

0 0
Sleeping Sound

Sleeping Sound

Get All The Support And Guidance You Need To Be A Success At Sleeping Well. This Book Is One Of The Most Valuable Resources In The World When It Comes To Getting The Rest You Need For Good Health.

Get My Free Ebook

Post a comment